deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02517021

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles in Patients Receiving Highly Emetogenic Chemotherapy

Sponsor: Helsinn Healthcare SA

Conditions Chemotherapy-Induced Nausea and Vomiting
Interventions Dexamethasone Netupitant/Palonosetron Pro-netupitant/Palonosetron
Updated 14 times since 2017 Last updated: Jun 18, 2018 Started: Nov 30, 2015 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chemotherapy-Induced Nausea and Vomiting and is currently completed. Helsinn Healthcare SA leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Dec 2018 · 5 months · monthly snapshot~Dec 2018 – ~Jul 2020 · 19 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Oct 2021 — Dec 2022 [monthly]

    Completed PHASE3

  2. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE3

  3. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE3

  4. Dec 2018 — Jul 2020 [monthly]

    Completed PHASE3

  5. Jul 2018 — Dec 2018 [monthly]

    Completed PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE3

  7. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE3

  8. Feb 2017 — Apr 2018 [monthly]

    Completed PHASE3

  9. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helsinn Healthcare SA
  • PSI CRO
Data source: Helsinn Healthcare SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Ashkelon, Israel , Avellino, Italy , Beersheba, Israel , Belgrade, Serbia , Bielefeld, Germany , Bloomington, United States , Brno, Czechia , Canton, United States , Chernivtsi, Ukraine and 50 more locations